ESR1 and breast carcinoma: In patients, ER-positive tumors are more differentiated and have lower metastatic potential than ER-negative tumors, suggesting a protective role of the estrogen receptor in tumor progression, and human breast cancer cells are more responsive to antiestrogens[18].